3-Amino-1-Adamantanol CAS 702-82-9 Puritas >99.0% (HPLC) Factory

Description:

Nomen chemicum: 3-Amino-1-Adamantanol

CAS: 702-82-9

Aspectus: Crystallinus Powder Alba

Puritas: >99.0% (HPLC) (basis siccum)

Medium API (CAS 274901-16-5) in tractatione Type 2 Diabetes Mellitus (T2DM)

Inquiry: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Manufacturer Supple intermedia:
CAS: 274901-16-5
3-Amino-1-Adamantanol CAS: 702-82-9
L-Prolinamide CAS: 7531-52-4
Boc-L-Proline CAS: 15761-39-4
Pyrrolidinecarbonitrile CAS: 207557-35-5

Chemical Properties:

Nomen chemicum	3-Amino-1-Adamantanol
Synonyma	1-Amino-3-Hydroxyadamantane;3-Amino-1-Hydroxyadamantane
CAS Number	702-82-9
CATTUS Number	RF-PI102
Stock Status	In Stock, Productio Capacitas 800MT/Annus
Formulae hypotheticae	C₁₀H₁₇NO
M. Pondus	167.25
Solubilitas	Solutum in Organicis solvendis et insolubile in aqua
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Crystallina pulveris alba
Puritas / Analysis Methodus	>99.0% (HPLC) (sicca basis)
Aqua (auctore Karl Fischer)	<0.50%
Residere in Ignition	<0.50%
Liquescens punctum	266.5℃~ 272.5℃
una immunditia	<0.50%
Totalis immunditias	<1.00%
Infrared Imaginis	Conformat ut Structure
Test Standard	Enterprise Standard
Consuetudinem	Medium API (CAS: 274901-16-5)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine & humore

commoda:

FAQ:

Applicatio:

Shanghai Ruifu Chemical Co., Ltd. est primarius fabrica et supplementum 3-Amino-1-Adamantanol (CAS: 702-82-9) magna qualitate.API (CAS: 274901-16-5) perstringitur ex 3-Amino-1-Adamantanol.API (CAS: 274901-16-5)est agentis oralis anti-hyperglycemici (medicamentum anti-diabeticum) novae dipeptidyli peptidasi-4 (DPP-4) inhibitoris medicamentorum ordinis.API (CAS: 274901-16-5) vetat inactionem GLP-I et GIP ab DPP-4, permittens GLP-1 et GIP potentiam insulin in cellulis insulinis potentiare et glucagonum reprimere per alpha cellulis emissio insulae de Langerhans in pancreate.Ostensum est reducere hyperglycemiam in diabete melliti specie 2 .Probatum est in Feb 2008 ab Europaea Medicamenta Agency ad usum intra EU et cum quibusdam restrictionibus in Australia PBS recensetur.